iMediSync Unveils World’s 1st Integrated Wireless Brain EEG at CES 2022 – iSyncWave™

The Company provides a 10-minute brain health screening opportunity through their press conference and visitation at the booth

iMediSync, a leading AI-driven early detection and therapeutic platform for optimal brain health from Seoul, South Korea announced today that the company will showcase its comprehensive EEG solution (hardware + software + remote telehealth solution), to perform brain mental health screening & predictive analysis of potential mental conditions in just 10 minutes.

They are launching their first therapeutic device – iSyncWave™, which integrates both EEG brain mapping and LED therapy at 2022 CES Las Vegas. An open-to-public CES Show Day press conference will take place on Jan 6th at the CES provided conference room.

iSyncWave™ is an innovative brain-scanning device with high-quality dry EEG sensors that autofit to various sizes and shapes, keeping 10 to 20 system locations and equipped with matching sex/age Norm DB.

As the company slogan states, “Overcome mental pandemic in just 10 minutes, “press and visitors can expect a complete analysis report of EEG (brainwave) and HRV (Heart rate variability) operated by AI deep learning algorithms in just 10 minutes to assess the condition of brain and dysfunctionality including the early diagnostic insights which could play a major role in discovering a neuro-related diseases in early stages.

Recently with the addition of software upgrades, and an FCC approval allowed the iSyncWave to be exported to the EU, Asia, and Australia already use for research and diagnostics.

“We will provide life-changing mental healthcare experience to introduce neuro-mental illness biomarker and the patent EEG/HRV technology,” says CEO Dr. Seung Wan Kang. “iMediSync takes its leap to be a trend leader in the field of telemedicine, and AI medicine, digital therapy will take place in a post-Covid-19 era as an optimized individual mental healthcare service provider.”

iMediSync proposes an EEG-centric global vision of integrated telemental health care & CNS drug development platform while cooperating with various neurologists, hospitals in South Korea in the field of Clinical Depression, Parkinson’s Disease, and other neuro-related diseases to expand the biomarker R&D pipeline. Active communication with global pharmaceutical companies are ongoing as well.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."
Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter's innovative technology the standard of care in cancer surgery."

By using this website you agree to accept Medical Device News Magazine Privacy Policy